STOCK TITAN

SpringWorks Therapeutics, Inc. - $SWTX STOCK NEWS

Welcome to our dedicated page for SpringWorks Therapeutics news (Ticker: $SWTX), a resource for investors and traders seeking the latest updates and insights on SpringWorks Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SpringWorks Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SpringWorks Therapeutics's position in the market.

Rhea-AI Summary

SpringWorks Therapeutics will present four abstracts at the 2024 ASCO Annual Meeting from May 31 to June 4, 2024. Key highlights include data from the Phase 2b ReNeu trial of mirdametinib for NF1-PN patients, showing significant tumor volume reductions and improved quality of life for both adults and children. Additionally, three analyses from the Phase 3 DeFi trial of nirogacestat for desmoid tumors will be presented, demonstrating consistent safety and efficacy. The ReNeu trial reported a 41% confirmed ORR in adults and 52% in children, with deep and durable tumor volume reductions. In the DeFi trial, nirogacestat showed improvements in progression-free survival and overall response rate in high-risk desmoid tumor patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
none
-
Rhea-AI Summary

SpringWorks Therapeutics, Inc. (SWTX) will participate in the BofA Securities 2024 Health Care Conference in Las Vegas. Management will engage in a fireside chat on May 14, 2024, at 3:40 p.m. PT / 6:40 p.m. ET. Investors can access the live webcast on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.63%
Tags
conferences
-
Rhea-AI Summary

SpringWorks Therapeutics reported first quarter 2024 financial results and highlighted recent business updates with $21.0 million in OGSIVEO net product revenue, FDA approval of a Supplemental NDA for OGSIVEO, validation from EMA for MAA of nirogacestat, initiation of rolling submission of NDA for mirdametinib, and Phase 2b ReNeu trial results acceptance at ASCO Annual Meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.45%
Tags
Rhea-AI Summary
SpringWorks Therapeutics announced that data from the Phase 2b ReNeu trial of mirdametinib in NF1-PN and additional data from the Phase 3 DeFi trial of OGSIVEO in adults with desmoid tumors have been accepted for presentation at the 2024 ASCO Annual Meeting. The company has initiated an NDA submission for mirdametinib. The presentations aim to reinforce the safety and efficacy profile of these investigational drugs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
none
-
Rhea-AI Summary
SpringWorks Therapeutics, a biopharmaceutical company, will report its first quarter 2024 financial results on May 2, 2024. The company focuses on severe rare diseases and cancer. Investors can join a live conference call and webcast to discuss the financial results and recent business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.72%
Tags
conferences earnings
-
Rhea-AI Summary
SpringWorks Therapeutics (SWTX) initiates NDA submission for mirdametinib, an MEK inhibitor, for NF1-PN treatment. Positive Phase 2b trial data show significant response rates and patient-reported improvements. Orphan Drug and Fast Track designations granted by FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
none
Rhea-AI Summary
SpringWorks Therapeutics, Inc. announces the validation of the Marketing Authorization Application (MAA) for nirogacestat by the European Medicines Agency (EMA) for the treatment of desmoid tumors. Nirogacestat showed significant improvements in progression-free survival, objective response rate, and patient-reported outcomes in the Phase 3 DeFi trial, positioning it as a potential first therapy for desmoid tumors in the EU.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
none
-
Rhea-AI Summary
SpringWorks Therapeutics, Inc. reported $5.4 million in net product revenue for OGSIVEO in the first partial quarter post-FDA approval. They submitted a Marketing Authorization Application for nirogacestat for desmoid tumors in Europe. Positive Phase 2b ReNeu trial data for mirdametinib in NF1-PN was presented, with plans to submit an NDA in 2024. SW-682 IND was submitted and FDA cleared for Phase 1a trial. The company ended 2023 with $662.6 million in cash, cash equivalents, and marketable securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.41%
Tags
-
Rhea-AI Summary
SpringWorks Therapeutics, Inc. (SWTX) will present at investor conferences including TD Cowen 44th Annual Health Care Conference and Barclays 26th Annual Global Healthcare Conference. Webcasts will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
conferences
Rhea-AI Summary
SpringWorks Therapeutics, Inc. (SWTX) will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 8, 2024. The event will be held in New York, New York, at 2:00 p.m. ET. The live webcast can be accessed on the company's website, with a replay available for a limited time after the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
conferences
SpringWorks Therapeutics, Inc.

Nasdaq:SWTX

SWTX Rankings

SWTX Stock Data

3.13B
68.01M
2.69%
107.54%
14.39%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
STAMFORD

About SWTX

springworks therapeutics is a mission-driven medicines company dedicated to developing innovative potential new treatments for unserved and underserved patient communities. originally conceived by pfizer, springworks presents a groundbreaking new model for collaboration rooted in connecting scientists, biopharmaceutical partners, patient groups, funders and philanthropists to advance and deliver transformative science to patients. through our partnerships, we remain focused on providing innovative treatments an additional avenue for development, with our launch pipeline focused on advancing potential programs for four diseases, all of which currently have no cure, including desmoid tumor, neurofibromatosis, hereditary xerocytosis and post-traumatic stress disorder. our name is a reflection of our approach to drug development: we’re springing into action to deliver treatments to people who are in great need and without alternatives.